Terkko Navigator / Leppä, S(irpa)*

Soluble PD-1 but Not PD-L1 Levels Predict Poor Outcome in Patients with High-Risk Diffuse Large B-Cell Lymphoma.

Immunogenomic Landscape of Hematological Malignancies.

Molecular background delineates outcome of double protein expressor diffuse large B-cell lymphoma.

Low Absolute Lymphocyte Counts in the Peripheral Blood Predict Inferior Survival and Improve the International Prognostic Index in Testicular Diffuse Large B-Cell Lymphoma.

Immunogenomic Landscape of Hematological Malignancies.

Adverse prognostic impact of regulatory T-cells in testicular diffuse large B-cell lymphoma.

Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis.

Mutational dynamics and immune evasion in diffuse large B-cell lymphoma explored in a relapse-enriched patient series.

Prognostic Impact of Tumor-Associated Macrophages on Survival Is Checkpoint Dependent in Classical Hodgkin Lymphoma.

STAT3 Mutation Is Associated with STAT3 Activation in CD30+ ALK- ALCL.

Immune cell constitution in the tumor microenvironment predicts the outcome in diffuse large B-cell lymphoma.

Long-term safety and efficacy of the PI3K- inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study.

Drug screening approach combines epigenetic sensitization with immunochemotherapy in cancer.

Whole Exome and Transcriptome Sequencing in 1042 Cases Reveals Distinct Clinically Relevant Genetic Subgroups of Follicular Lymphoma.

Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study.

Pixantrone beyond monotherapy: a review.

Distinct subtypes of diffuse large B-cell lymphoma defined by hypermutated genes.

Intravenous but not intrathecal central nervous system-directed chemotherapy improves survival in patients with testicular diffuse large B-cell lymphoma.

Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma.

Clinical features and outcome of the patients with sinonasal tract diffuse large B-cell lymphoma in the pre and rituximab eras.

T-cell inflamed tumor microenvironment predicts favorable prognosis in primary testicular lymphoma.

PD-L1+ tumor-associated macrophages and PD-1+ tumor infiltrating lymphocytes predict survival in primary testicular lymphoma.

Up-front rituximab maintenance improves outcome in patients with follicular lymphoma: a collaborative Nordic study.

Identifying differentially methylated sites in samples with varying tumor purity.

HIV infection and cancer.

MicroRNAs regulate key cell survival pathways and mediate chemosensitivity during progression of diffuse large B-cell lymphoma.

Clinical significance of gene defects in B-cell lymphomas.

Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma.

Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma.

Alternative splicing discriminates molecular subtypes and has prognostic impact in diffuse large B-cell lymphoma.

Clinical findings in 25 patients with sinonasal or nasopharyngeal extramedullary plasmacytoma in a four-decade single-centre series.

Enteropathy-associated T cell lymphoma subtypes are characterized by loss of function of SETD2.

Deltex-1 mutations predict poor survival in diffuse large B-cell lymphoma.

Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study.

Plasma immunoprofiling of patients with high-risk diffuse large B-cell lymphoma: a Nordic Lymphoma Group study.

FGF21 is a biomarker for mitochondrial translation and mtDNA maintenance disorders.

Risk Factors and Outcomes for Patients With Follicular Lymphoma Who Had Histologic Transformation After Response to First-Line Immunochemotherapy in the PRIMA Trial.

Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma.

Clinical findings of extranodal SNT lymphoid malignancies in a four-decade single-centre series.

Total peroxiredoxin expression is associated with survival in patients with follicular lymphoma.

Allogeneic Haematopoietic Stem Cell Transplantation for Patients with Cutaneous T-cell Lymphoma.

Constant pattern of relapse in primary central nervous lymphoma patients treated with high-dose methotrexate combinations. A Finnish retrospective study.

Identification of homozygous deletion in ACAN and other candidate variants in familial classical Hodgkin lymphoma by exome sequencing.

Activating mutations of STAT5B and STAT3 in lymphomas derived fromγδ-T or NK cells.

[Prognostic factors and treatment of diffuse large cell B-cell lymphoma].

Successful change of treatment strategy in elderly patients with primary central nervous system lymphoma by de-escalating induction and introducing temozolomide maintenance: results from a phase 2 study by The Nordic Lymphoma Group.

Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma: a correlative study from a Nordic phase II trial.

FDG-PET/CT after one cycle of chemotherapy in patients with diffuse large B-cell lymphoma: Results of a Nordic/US intergroup study.

Combining MYC, BCL-2 and TP53 gene and protein expression alterations improves risk stratification in diffuse large B-cell lymphoma.

Rituximab maintenance obviates the poor prognosis associated with circulating lymphoma cells in patients with follicular lymphoma.